Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
Toripalimab-tpzi is a programmed death receptor-1 (PD-1) blocking antibody. Toripalimab-tpzi is a humanized immunoglobulin G4 (IgG4) kappa immunoglobulin that has a predicted molecular weight of approximately 150 kDa. It is expressed in a recombinant Chinese Hamster Ovary (CHO) mammalian cell expression system.
LOQTORZI (toripalimab-tpzi) injection is a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution for intravenous use supplied in a single-dose vial. Each vial contains 240 mg of LOQTORZI in 6 mL of solution. Each mL of solution contains 40 mg toripalimab-tpzi, citric acid monohydrate (0.51 mg), mannitol (25 mg), polysorbate 80 (0.20 mg), sodium chloride (2.92 mg), sodium citrate (4.65 mg), and Water for Injection, USP, at pH 6.0.
LOQTORZI is indicated, in combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or with recurrent, locally advanced nasopharyngeal carcinoma (NPC).
LOQTORZI is indicated, as a single agent, for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy.
The recommended dosages of LOQTORZI are provided in Table 1. Administer as recommended [see Preparation And Administration].
Table 1: Recommended Dosage
| Indication | Recommended Dosage of LOQTORZI | Duration of Treatment |
| First-line NPC | 240 mg every three weeks | Until disease progression, unacceptable toxicity, or up to 24 months. |
| Recurrent NPC | 3 mg/kg every two weeks | Until disease progression or unacceptable toxicity. |
No dose reductions of LOQTORZI are recommended. In general, withhold LOQTORZI for severe (Grade 3) immune-mediated adverse reactions. Permanently discontinue LOQTORZI for life-threatening (Grade 4) immune-mediated adverse reactions, recurrent severe (Grade 3) immune-mediated reactions that require systemic immunosuppressive treatment, or an inability to reduce prednisone to 10 mg per day or less (or equivalent) within 12 weeks of initiating steroids.
Dosage modifications for LOQTORZI for adverse reactions that require management different from these general guidelines are summarized in Table 2.
Table 2: Recommended Dosage Modifications for Adverse Reactions
| Adverse Reaction | Severity1 | Dose Modification |
| Immune-Related Adverse Reactions [see WARNINGS AND PRECAUTIONS] | ||
| Pneumonitis | Grade 2 | Withhold2 |
| Grades 3 or 4 | Permanently discontinue | |
| Colitis | Grade 2 or 3 | Withhold2 |
| Grade 4 | Permanently discontinue | |
| Hepatitis with no tumor involvement of the liver | AST/ALT increases to more than 3 and up to 8 times ULN or Total bilirubin increases to more than 1.5 and up to 3 times ULN |
Withhold2 |
| AST or ALT increases to more than 8 times ULN or Total bilirubin increases to more than 3 times ULN |
Permanently discontinue | |
| Hepatitis with tumor involvement of the liver3 | Baseline AST or ALT is more than 1 and up to 3 times ULN and increases to more than 5 and up to 10 times ULN or Baseline AST or ALT is more than 3 and up to 5 times ULN and increases to more than 8 and up to 10 times ULN |
Withhold2 |
| Baseline AST or ALT is above the ULN and increases to more than 10 times ULN or Total bilirubin increases to more than 3 times ULN |
Permanently discontinue | |
| Endocrinopathies | Grades 3 or 4 | Withhold until clinically stable or permanently discontinue depending on severity2 |
| Nephritis with Renal Dysfunction | Grade 2 or 3 increased blood creatinine | Withhold2 |
| Grade 4 increased blood creatinine | Permanently discontinue | |
| Exfoliative Dermatologic Conditions | Suspected SJS, TEN, or DRESS | Withhold2 |
| Confirmed SJS, TEN, or DRESS | Permanently discontinue | |
| Myocarditis | Grades 2, 3, or 4 | Permanently discontinue |
| Neurological toxicities | Grade 2 | Withhold2 |
| Grade 3-4 | Permanently discontinue | |
| Other Adverse Reactions | ||
| Infusion-related reactions [see WARNINGS AND PRECAUTIONS] | Grade 1 or 2 | Interrupt or slow the rate of infusion |
| Grade 3 or 4 | Stop infusion Permanently discontinue | |
| 1 Based on National Cancer Institute (NCI) Common Terminology for Adverse Events (CTCAE) version 5.0 2 Resume LOQTORZI in patients with complete or partial resolution to Grade 0-1 after corticosteroid taper. Permanently discontinue if no complete or partial resolution within 12 weeks of initiating steroids or inability to reduce prednisone to 10 mg per day or less (or equivalent) within 12 weeks of initiating steroids. 3 If AST and ALT are less than or equal to ULN at baseline in patients with liver involvement, withhold or permanently discontinue LOQTORZI based on recommendations for hepatitis with no liver involvement. ALT=alanine aminotransferase, AST=aspartate aminotransferase, DRESS=drug rash with eosinophilia and systemic symptoms, SJS=Stevens Johnson syndrome, TEN=toxic epidermal necrolysis, ULN=upper limit of normal |
||
LOQTORZI does not contain a preservative.
If the diluted solution is not administered immediately, store either:
Or
Do not freeze.
Injection: 240 mg/6 mL (40 mg/mL) clear to slightly opalescent, colorless to slightly yellow solution in a single-dose vial.
LOQTORZI (toripalimab-tpzi), injection is a clear to slightly opalescent, colorless to slightly yellow solution supplied in a carton containing one 240 mg/6 mL (40 mg/mL) single-dose vial (NDC 70114-340-01).
Store vials refrigerated at 2°C to 8°C (36°F to 46°F) in original carton to protect from light. Do not freeze. Do not shake.
Manufactured by: Coherus BioSciences, Inc. 333 Twin Dolphin Drive, Suite 600 Redwood City, CA 94065, USA. Revised: Oct 2023.
The following clinically significant adverse reactions are described elsewhere in the labeling:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The data described in the WARNINGS AND PRECAUTIONS section reflect exposure to LOQTORZI at a dose of 240 mg every 3 weeks in combination with up to 6 cycles of cisplatin and gemcitabine, followed by LOQTORZI 240 mg IV every 3 weeks, in 146 patients with NPC enrolled in a randomized, double-blind, placebo-controlled trial (JUPITER-02). Among the 146 patients, 73% were exposed to LOQTORZI for 6 months or more and 54% were exposed for 12 months or more. The most common adverse reactions (≥ 20%) were: nausea (71%), vomiting (68%), decreased appetite (55%), constipation (39%), hypothyroidism (38%), rash (36%), pyrexia (32%), diarrhea (31%), peripheral neuropathy (30%), cough (26%), musculoskeletal pain (25%), upper respiratory infection (23%), insomnia (23%), dizziness (21%), and malaise (21%). The most common Grade 3 or 4 laboratory abnormalities (≥2%) were: decreased neutrophils (58%), decreased lymphocytes (57%), decreased hemoglobin (50%) decreased platelets (33%), decreased potassium (10%), decreased sodium (9%), increased alanine aminotransferase (6%) increased or decreased magnesium (4.2% each), decreased calcium (3.5%), increased aspartate aminotransferase (2.7%), and bilirubin increased (2.1%).
The data described in the WARNINGS AND PRECAUTIONS section also reflects exposure to LOQTORZI as a single agent at a dose of 3 mg/kg IV every 2 weeks in 851 patients enrolled in 12 trials: one randomized, active-controlled trial and 11 open-label, non-randomized trials. The tumor types included nasopharyngeal carcinoma (n=193) or other types of tumors (n=658).
Among the 851 patients treated with LOQTORZI as a single agent, 35% were exposed for 6 months or more and 20% were exposed for 12 months or more. In this pooled safety population, the most common (≥20%) adverse reactions were: fatigue (22%), hypothyroidism (20%), and musculoskeletal pain (20%). The most common Grade 3 or 4 laboratory abnormalities (≥2%), were decreased sodium (9%), decreased lymphocytes (8%), decreased hemoglobin (7%), decreased fibrinogen (4.5%), increased lipase (4.0%), increased amylase (2.9%), decreased phosphate (2.8%), increased aspartate aminotransferase (2.6%), increased glucose (2.5%), and increased triglycerides (2.1%).
The safety of LOQTORZI in combination with cisplatin and gemcitabine was evaluated in JUPITER-02 [see Clinical Studies]. Key eligibility criteria were recurrent locally advanced or metastatic nasopharyngeal carcinoma (NPC) not previously treated with systemic chemotherapy for recurrent or metastatic disease. Patients with recurrent NPC after treatment with curative intent were required to have an interval of at least 6 months between the last dose of radiotherapy or chemotherapy and recurrence. Patients received LOQTORZI 240 mg (n=146) or placebo intravenously (IV) every 3 weeks (n=143), in combination with cisplatin 80 mg/m² IV every 3 weeks and gemcitabine 1000 mg/m² IV days 1 and 8 for up to 6 cycles followed by LOQTORZI 240 mg or placebo IV every 3 weeks until disease progression, unacceptable toxicity, or completion of 2 years of treatment. Among patients who received LOQTORZI, 73% were exposed for 6 months or longer and 54% were exposed for greater than one year.
The median age of patients who received LOQTORZI was 48 years (range: 19 to 72), 83% male, 100% Asian, 60% had recurrent disease, and 40% presented with metastatic disease. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) was 0 (57%) or 1 (43%). Approximately 59% of patients had received at least one prior systemic therapy for locally advanced disease and 60% had received prior radiation therapy.
Serious adverse reactions occurred in 43% of patients receiving LOQTORZI in combination with cisplatin and gemcitabine. Serious adverse drug reactions in ≥ 2% were thrombocytopenia (14%), neutrophil count decreased (10%), pneumonia (10%), anemia (9%), abnormal hepatic function (2.7%), and rash (2.1%). Of the patients who received LOQTORZI in combination with cisplatin and gemcitabine, there were three fatal adverse reactions (2.1%) one due to epistaxis; one due to intracranial hemorrhage associated with immune-related thrombocytopenia and coagulopathy; and one due to pneumonia.
Permanent discontinuation of LOQTORZI, when given in combination with cisplatin and gemcitabine, due to an adverse reaction occurred in 12% of patients. Adverse reactions resulting in permanent discontinuation of LOQTORZI in ≥1% were pneumonia (2.1%), pulmonary tuberculosis (1.4%), rash (1.4%), and vomiting (1.4%).
Dosage interruptions of LOQTORZI due to an adverse reaction occurred in 50% of patients. Adverse reactions which required dosage interruption in ≥2% were anemia (17%), decreased neutrophils (12%), thrombocytopenia (12%), acute kidney injury (4.1%), pneumonia (6%), fatigue (2.7%), upper respiratory infection (2.7%), and hypothyroidism (2.1%).
Table 3 summarizes the adverse reactions in JUPITER-02.
Table 3: Adverse Reactions (≥ 10%) in Patients with Recurrent, Locally Advanced or Metastatic NPC Who Received LOQTORZI in Combination with Cisplatin and Gemcitabine in JUPITER-02
| Adverse Reaction1 | LOQTORZI Cisplatin/ Gemcitabine N = 146 |
Placebo Cisplatin/ Gemcitabine N = 143 |
||
| All Grades (%) | Grade 3 or 4 (%) | All Grades (%) | Grade 3 or 4 (%) | |
| Gastrointestinal Disorders | ||||
| Nausea | 71 | 1.4 | 84 | 2.8 |
| Vomiting | 68 | 2.1 | 66 | 2.1 |
| Constipation | 39 | 0 | 46 | 0 |
| Diarrhea | 31 | 1.4 | 23 | 0 |
| Stomatitis2 | 12 | 0 | 8 | 0.7 |
| Metabolism and Nutrition Disorders | ||||
| Decreased appetite | 55 | 0.7 | 63 | 0 |
| Endocrine Disorders | ||||
| Hypothyroidism3 | 38 | 0.7 | 17 | 0 |
| Skin Disorders | ||||
| Rash4 | 36 | 3.4 | 28 | 2.8 |
| Pruritus | 17 | 0 | 8 | 0 |
| General Disorders | ||||
| Pyrexia | 32 | 1.4 | 24 | 0.7 |
| Malaise | 21 | 0.7 | 20 | 0 |
| Fatigue5 | 19 | 0.7 | 22 | 2.1 |
| Nervous System Disorders | ||||
| Peripheral neuropathy6 | 30 | 0 | 31 | 0.7 |
| Dizziness | 21 | 0 | 22 | 0.7 |
| Headache | 18 | 0 | 23 | 0.7 |
| Respiratory, Thoracic and Mediastinal Disorders | ||||
| Cough7 | 26 | 0 | 27 | 0 |
| Musculoskeletal Disorders | ||||
| Musculoskeletal pain8 | 25 | 0 | 25 | 0.7 |
| Infections | ||||
| Upper respiratory infection9 | 23 | 3.4 | 13 | 2.8 |
| Pneumonia10 | 18 | 11 | 7 | 3.5 |
| Psychiatric Disorders | ||||
| Insomnia | 23 | 0 | 17 | 0 |
| Vascular Disorders | ||||
| Epistaxis | 10 | 1.3 | 13 | 2.8 |
| Hypertension11 | 10 | 6 | 6 | 4.2 |
| 1NCI CTCAE v5.0. 2Includes mouth ulceration, stomatitis, and radiation stomatitis. 3Includes hypothyroidism, tri-iodothyronine decreased, tri-iodothyronine free decreased, and thyroiditis. 4Includes acneiform dermatitis, allergic dermatitis, catheter-site rash, dermatitis, drug eruption, eczema, erythema, macule, maculopapular rash, palmar-plantar erythrodysesthesia syndrome, papule, pruritic rash, rash, and urticaria. 5Includes asthenia and fatigue. 6Includes hypoesthesia, neuralgia, neuropathy peripheral, paresthesia, peripheral sensory neuropathy. 7Includes cough and productive cough. 8Includes back pain, bone pain, musculoskeletal chest pain, musculoskeletal pain, myalgia, neck pain, pain in extremity, pain in jaw. 9Includes acute sinusitis, bronchitis, laryngitis, nasopharyngitis, pharyngitis, respiratory tract infection, rhinitis, sinusitis, and upper respiratory tract infection. 10Includes aspiration pneumonia and pneumonia 11Includes blood pressure increased, blood pressure systolic increased, hypertension, and hypertensive crisis. |
||||
Table 4 summarizes the laboratory abnormalities in JUPITER-02.
Table 4: Select Laboratory Abnormalities (≥20%) That Worsened from Baseline in Patients with Recurrent, Locally Advanced or Metastatic NPC Who Received LOQTORZI in Combination with Cisplatin and Gemcitabine in JUPITER-02
| Laboratory Abnormalities* | LOQTORZI Cisplatin/ Gemcitabine | Placebo Cisplatin/ Gemcitabine | ||
| All Grades†(%) | Grade 3 or 4 (%) | All Grades (%) | Grades 3 or 4 (%) | |
| Hematology | ||||
| Decreased hemoglobin | 94 | 50 | 97 | 38 |
| Decreased neutrophils | 91 | 58 | 95 | 63 |
| Decreased lymphocytes | 88 | 57 | 88 | 49 |
| Decreased platelets | 71 | 33 | 66 | 31 |
| Chemistry | ||||
| Decreased magnesium | 78 | 4.2 | 77 | 8 |
| Decreased sodium | 63 | 9 | 62 | 6 |
| Increased alanine aminotransferase | 58 | 6 | 50 | 3.5 |
| Increased aspartate aminotransferase | 58 | 2.7 | 53 | 4.9 |
| Decreased albumin | 49 | 0 | 48 | 0 |
| Decreased calcium | 45 | 3.5 | 46 | 4.2 |
| Increased lactate dehydrogenase | 42 | 0 | 35 | 0 |
| Increased calcium | 39 | 0 | 35 | 0.7 |
| Decreased potassium | 40 | 10 | 39 | 8 |
| Increased creatinine | 39 | 0.7 | 41 | 0 |
| Increased alkaline phosphatase | 27 | 0 | 27 | 0 |
| Decreased glucose | 23 | 1.4 | 16 | 0 |
| *Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: LOQTORZI/chemotherapy (range: 139 to 146 patients) and placebo/chemotherapy (range: 136 to 143 patients). † Graded per NCI CTCAE v5.0; AKP=alkaline phosphatase. ALT=alanine aminotransferase. AST=aspartate aminotransferase. |
||||
The safety of LOQTORZI was evaluated in POLARIS-02. Eligible patients had previously treated unresectable or metastatic NPC. Patients received LOQTORZI 3 mg/kg every 2 weeks as an intravenous infusion until disease progression or unacceptable toxicity. Among patients who received LOQTORZI, 33% were exposed for 6 months or longer and 21% were exposed for greater than one year.
The median age of patients who received LOQTORZI was 46 years (range: 22 to 71), 83% male, 100% Asian, Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 (35%) or 1 (65%) and median weight 59 kg (range: 32 to 101 kg).
Serious adverse reactions occurred in 24% of patients who received LOQTORZI. Serious adverse drug reactions in (≥2%) were pneumonia (4.7%), abnormal hepatic function (2.6%), and hyperbilirubinemia (2.1%). Fatal adverse reactions occurred in 3.7% of patients who received LOQTORZI, including death not otherwise specified (1.6%), tumor hemorrhage (0.5%), hepatic failure and thrombocytopenia (0.5%), hyponatremia (0.5%), and sudden death (0.5%).
Permanent discontinuation of LOQTORZI due to an adverse reaction occurred in 9% of patients. Adverse reaction resulting in permanent discontinuation of LOQTORZI in ≥1% included pneumonia (1.1%), abnormal hepatic function (1.1%), and hyperbilirubinemia (1.1%).
Dosage interruptions due to an adverse reaction occurred in 23% of patients. Adverse reactions which required dosage interruption in ≥1% were pneumonia (2.1%), thrombocytopenia (2.1%), fatigue (1.6%), hyperbilirubinemia (1.6%), anemia (1.1%), decreased appetite (1.1%), abnormal hepatic function (1.1%), hypothyroidism (1.1%), and pneumonitis (1.1%).
Table 5 summarizes the adverse reactions in POLARIS-02.
Table 5: Adverse Reactions (≥10%) in Patients with Previously Treated, Unresectable or Metastatic NPC Who Received LOQTORZI in POLARIS-02
| Adverse Reaction* | LOQTORZI N=190 |
|
| All Grades (%) | Grade 3 or 4 (%) | |
| Endocrine Disorders | ||
| Hypothyroidism1 | 27 | 0 |
| General Disorders | ||
| Fatigue2 | 22 | 2.6 |
| Pyrexia | 16 | 0 |
| Respiratory Disorders | ||
| Cough3 | 20 | 0 |
| Musculoskeletal Disorders | ||
| Musculoskeletal Pain4 | 18 | 1.1 |
| Metabolism and Nutrition | ||
| Decreased Appetite | 13 | 1.1 |
| Gastrointestinal Disorders | ||
| Constipation | 11 | 0 |
| Skin and Subcutaneous Disorders | ||
| Pruritus | 11 | 0 |
| Rash5 | 11 | 0 |
| Investigations | ||
| Weight Decreased | 11 | 0 |
| *Toxicity was graded per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03. 1Includes hypothyroidism, thyroiditis, tri-iodothyronine decreased, and tri-iodothyronine free decreased 2Includes fatigue and asthenia 3Includes cough and productive cough. 4Includes musculoskeletal pain and myalgia. 5Includes dermatitis allergic, eczema, and rash. |
||
Table 6 summarizes the laboratory abnormalities in POLARIS-02.
Table 6: Select Laboratory Abnormalities (≥20%) That Worsened from Baseline in Patients with Previously Treated, Unresectable or Metastatic NPC Who Received LOQTORZI in POLARIS-02
| LOQTORZI | ||
| All Grades (%)1 | Grade 3 or 4 (%)1 | |
| Chemistry | ||
| Decreased albumin | 38 | 0.5 |
| Decreased sodium | 35 | 11 |
| Decreased phosphate | 32 | 3.2 |
| Increased aspartate aminotransferase | 30 | 3.8 |
| Decreased calcium | 29 | 0.5 |
| Increased alkaline phosphatase | 28 | 2.2 |
| Increased triglyceride | 26 | 1.1 |
| Increased glucose | 24 | 1.1 |
| Increased alanine aminotransferase | 23 | 1.6 |
| Hematology | ||
| Decreased lymphocytes | 52 | 9 |
| Decreased hemoglobin | 43 | 6 |
| 1 Toxicity graded per NCI CTCAE v4.03. The denominator used to calculate the rate varied from 141 to 186 based on the number of patients with a baseline value and at least one post-treatment value. | ||
No Information provided
Included as part of the PRECAUTIONS section.
LOQTORZI is a monoclonal antibody that belongs to a class of drugs that bind to either the programmed death receptor-1 (PD-1) or PD-ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions. Important immune-mediated adverse reactions listed under WARNINGS AND PRECAUTIONS may not include all possible severe and fatal immune-mediated reactions.
Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue and can affect more than one body system simultaneously. Immune-mediated adverse reactions can occur at any time after starting PD-1/PD-L1 blocking antibody. While immune-mediated adverse reactions usually manifest during treatment with PD-1/PD-L1 blocking antibodies, immune-mediated adverse reactions can also manifest after discontinuation of PD-1/PD-L1 blocking antibodies.
Early identification and management of immune-mediated adverse reactions are essential to ensure safe use of PD-1/PD-L1 blocking antibodies. Monitor closely for symptoms and signs that may be clinical manifestations of underlying immune-mediated adverse reactions. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.
Withhold or permanently discontinue LOQTORZI depending on severity [see DOSAGE AND ADMINISTRATION]. In general, if LOQTORZI requires interruption or discontinuation, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroid therapy.
Toxicity management guidelines for adverse reactions that do not necessarily require systemic steroids (e.g., endocrinopathies and dermatologic reactions) are discussed below.
LOQTORZI In Combination With Cisplatin And Gemcitabine
LOQTORZI in combination with cisplatin and gemcitabine can cause immune-mediated pneumonitis. In patients treated with other PD-1/PD-L1 blocking antibodies, the incidence of pneumonitis is higher in patients who have received prior thoracic radiation. Immune-mediated pneumonitis occurred in 2.1% (3/146) of patients receiving LOQTORZI, including Grade 2 (1.4%) adverse reactions. Pneumonitis resolved in 67% (2/3) of these patients.
LOQTORZI As A Single-Agent
LOQTORZI can cause immune-mediated pneumonitis. In patients treated with other PD-1/PD-L1 blocking antibodies, the incidence of pneumonitis is higher in patients who have received prior thoracic radiation. Immune-mediated pneumonitis occurred in 2.6% (22/851) of patients receiving LOQTORZI, including fatal (0.2%), Grade 3 (0.7%), and Grade 2 (1.1%) adverse reactions. Systemic corticosteroids were required in 82% (18/22) of patients with pneumonitis. Pneumonitis led to permanent discontinuation of LOQTORZI in 1.2% (10/851) of patients. Pneumonitis resolved in 23% (5/22) of these patients.
LOQTORZI can cause immune-mediated colitis, which may present with diarrhea. Cytomegalovirus (CMV) infection/reactivation has been reported in patients with corticosteroidrefractory immune-mediated colitis. In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies.
LOQTORZI As A Single-Agent
Immune-mediated colitis occurred in 0.4% (3/851) of patients receiving LOQTORZI, including Grade 3 (0.2%) and Grade 2 (0.1%) adverse reactions. Colitis resolved in all 3 patients.
LOQTORZI In Combination With Cisplatin And Gemcitabine
LOQTORZI in combination with cisplatin and gemcitabine can cause immune-mediated hepatitis. Immune-mediated hepatitis occurred in 0.7% (1/146) of patients receiving LOQTORZI in combination with cisplatin and gemcitabine, which was a Grade 3 (0.7%) adverse reaction. The patient with immune-mediated hepatitis required systemic corticosteroids.
LOQTORZI As A Single-Agent
LOQTORZI can cause immune-mediated hepatitis. Immune-mediated hepatitis occurred in 3.3% (28/851) of patients receiving LOQTORZI, including Grade 4 (0.8%), Grade 3 (2.1%), and Grade 2 (0.4%) adverse reactions. Hepatitis led to permanent discontinuation of LOQTORZI in 1.1% of patients and withholding of LOQTORZI in 0.8% of patients. Hepatitis resolved in 54% (15/28) of these patients.
Adrenal Insufficiency
LOQTORZI can cause primary or secondary adrenal insufficiency. For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment, including hormone replacement as clinically indicated. Withhold or permanently discontinue LOQTORZI depending on severity [see DOSAGE AND ADMINISTRATION].
LOQTORZI As A Single-Agent
Adrenal insufficiency occurred in 0.5% (4/851) of the patients receiving LOQTORZI, including Grade 2 (0.4%) and Grade 1 (0.1%) adverse reactions. Systemic corticosteroids were required in 75% (3/4) of the patients with adrenal insufficiency. Adrenal insufficiency led to withholding of LOQTORZI in 0.1% (1/851) of patients. In the one patient in whom LOQTORZI was withheld, LOQTORZI was reinitiated after symptom improvement.
LOQTORZI can cause immune-mediated hypophysitis. Hypophysitis can present with acute symptoms associated with mass effects such as headache, photophobia, or visual field defects. Hypophysitis can cause hypopituitarism. Initiate hormone replacement as indicated. Withhold or permanently discontinue LOQTORZI depending on severity [see DOSAGE AND ADMINISTRATION].
LOQTORZI As A Single-Agent
Hypophysitis occurred in 0.4% (3/851) of patients receiving LOQTORZI, including Grade 3 (0.2%) and Grade 2 (0.1%) adverse reactions. All three patients received systemic corticosteroids. Hypophysitis led to permanent discontinuation of LOQTORZI in 0.1% (1/851) of patients and withholding of LOQTORZI in 0.1% (1/851) of patients. The one patient in whom LOQTORZI was withheld reinitiated LOQTORZI.
Thyroid Disorders
LOQTORZI can cause immune-mediated thyroid disorders. Thyroiditis can present with or without endocrinopathy. Hypothyroidism can follow hyperthyroidism. Initiate hormone replacement for hypothyroidism or institute medical management of hyperthyroidism as clinically indicated. Withhold or permanently discontinue LOQTORZI depending on severity [see DOSAGE AND ADMINISTRATION].
LOQTORZI In Combination With Cisplatin And Gemcitabine
Thyroiditis occurred in 2.1% (3/146) of patients receiving LOQTORZI in combination with cisplatin and gemcitabine, including Grade 2 (1.4%). Three patients required thyroid hormone replacement therapy. Thyroiditis resolved in one of the 3 patients.
Hyperthyroidism occurred in 1.4% (2/146) of patients receiving LOQTORZI in combination with cisplatin and gemcitabine. Hyperthyroidism resolved in these 2 patients.
Hypothyroidism occurred in 30% (44/146) of patients receiving LOQTORZI in combination with cisplatin and gemcitabine, including Grade 2 (24%) and Grade 1 (6%). Eighty percent of the 44 patients required thyroid hormone replacement therapy. LOQTORZI was withheld in 2.1% (3/146) of the patients. Of the 3 patients in whom LOQTORZI was withheld, 2 patients reinitiated LOQTORZI.
LOQTORZI As A Single-Agent
Thyroiditis occurred in 0.6% (5/851) of patients receiving LOQTORZI, including Grade 2 (0.1%). Two of these 5 patients received systemic corticosteroids and 2 required thyroid hormone replacement therapy. Thyroiditis resolved in 2 of the 5 patients.
Hyperthyroidism occurred in 7% (55/851) of patients receiving LOQTORZI, including Grade 2 (1.9%). Hyperthyroidism resolved in 85% (47/55) of the patients.
Hypothyroidism occurred in 15% (128/851) of patients receiving LOQTORZI, including Grade 2 (8%). Sixty three percent of the 128 patients required thyroid hormone replacement therapy.
LOQTORZI was withheld in 0.5% of patients. Of the 4 patients in whom LOQTORZI was withheld, 3 patients reinitiated LOQTORZI.
Type 1 Diabetes Mellitus, Which Can Present With Diabetic Ketoacidosis
Monitor patients for hyperglycemia or other signs and symptoms of diabetes. Initiate treatment with insulin as clinically indicated. Withhold or permanently discontinue LOQTORZI depending on severity [see DOSAGE AND ADMINISTRATION].
LOQTORZI As A Single-Agent
Diabetes mellitus occurred in 0.9% (8/851) of patients receiving LOQTORZI, including Grade 4 (0.1%), Grade 3 (0.7%), and Grade 2 (0.1%). Diabetes mellitus led to permanent discontinuation in 0.4% of patients. Six of the 8 (75%) patients with diabetes mellitus required long-term insulin therapy.
LOQTORZI In Combination With Cisplatin And Gemcitabine
LOQTORZI in combination with cisplatin and gemcitabine can cause immune-mediated nephritis. Immune-mediated nephritis occurred in 0.7% (1/146) of patients receiving LOQTORZI. The one patient with immune-mediated nephritis (Grade 4) required systemic corticosteroids and nephritis led to discontinuation of LOQTORZI. Nephritis resolved in this patient.
LOQTORZI As A Single-Agent
LOQTORZI can cause immune-mediated nephritis. Immune-mediated nephritis occurred in 0.5% (4/851) of patients receiving LOQTORZI, including Grade 3 (0.5%) adverse reactions. Nephritis resolved in 75% (3/4) of these patients.
LOQTORZI can cause immune-mediated rash or dermatitis. Exfoliative dermatitis, including Stevens-Johnson Syndrome (SJS), drug rash with eosinophilia and systemic symptoms (DRESS), and toxic epidermal necrolysis (TEN), has occurred with PD-1/PD-L1 blocking antibodies. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate nonexfoliative rashes. Withhold or permanently discontinue LOQTORZI depending on severity [see DOSAGE AND ADMINISTRATION].
LOQTORZI In Combination With Cisplatin And Gemcitabine
Immune-mediated dermatologic adverse reactions occurred in 8% (12/146) of patients receiving LOQTORZI, including Grade 3 (3.4%) and Grade 2 (1.4%) adverse reactions. Systemic corticosteroids were required in 25% (3/12) of the patients with immune-mediated dermatologic adverse reactions. Immune-mediated dermatologic adverse reactions led to permanent discontinuation of LOQTORZI in 2.1% (3) of patients. Immune-mediated dermatologic adverse reactions resolved in 92% (11/12) of these patients.
LOQTORZI As A Single-Agent
Immune-mediated dermatologic adverse reactions occurred in 4% (34/851) of patients receiving LOQTORZI, including Grade 3 (0.4%) and Grade 2 (1.4%) adverse reactions. Immune-mediated dermatologic adverse reactions led to withholding of LOQTORZI in 0.4% (3) of the patients. Systemic corticosteroids were required in 12% (4/34) of the patients with immune-mediated dermatologic adverse reactions. Immune-mediated dermatologic adverse reactions resolved in 71% (24/34) of these patients.
The following clinically significant immune-mediated adverse reactions occurred at an incidence of <1% (unless otherwise noted) in patients who received LOQTORZI or were reported with the use of other PD1/PD-L1 blocking antibodies. Severe or fatal cases have been reported for some of these adverse reactions.
Cardiac/Vascular: Myocarditis, pericarditis, vasculitis, pericardial effusion
Nervous System: Meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis (including exacerbation), Guillain-Barré syndrome, nerve paresis, autoimmune neuropathy
Ocular: Uveitis, iritis and other ocular inflammatory toxicities can occur. Some cases can be associated with retinal detachment. Various grades of visual impairment, including blindness, can occur. If uveitis occurs in combination with other immune-mediated adverse reactions, consider a Vogt-Koyanagi-Harada-like syndrome, as this may require treatment with systemic steroids to reduce the risk of permanent vision loss.
Gastrointestinal: Pancreatitis, to include increases in serum amylase and lipase levels, gastritis, duodenitis
Musculoskeletal and Connective Tissue: Myositis/polymyositis, rhabdomyolysis (and associated sequelae, including renal failure), arthritis, polymyalgia rheumatica, dermatomyositis
Endocrine: Hypoparathyroidism
Hematologic/Immune: Hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenic purpura, solid organ transplant rejection, other transplant (including corneal graft) rejection.
LOQTORZI can cause severe or life-threatening infusion-related reactions including hypersensitivity and anaphylaxis.
Infusion-related reactions have been reported in 4.1% of patients receiving LOQTORZI in combination with cisplatin and gemcitabine, including Grade 2 (0.7%) reactions.
Infusion-related reactions occurred in 2% of 851 patients receiving LOQTORZI as single agent, including Grade 3 (0.1%) and Grade 2 (0.6%). LOQTORZI was withheld for one Grade 3 infusion related reaction.
Monitor patients for signs and symptoms of infusion-related reactions including rigors, chills, wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever. Interrupt or slow the rate of infusion for mild (Grade 1) or moderate (Grade 2) infusion-related reactions. For severe (Grade 3) or life-threatening (Grade 4) infusion-related reactions, stop infusion and permanently discontinue LOQTORZI [see DOSAGE AND ADMINISTRATION].
Fatal and other serious complications can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after being treated with a PD-1/PD-L1 blocking antibody. Transplant-related complications include hyperacute graft-versus-host-disease  (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease (VOD) after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening therapy between PD-1/PD-L1 blockade and allogeneic HSCT.
Follow patients closely for evidence of transplant-related complications and intervene promptly. Consider the benefit versus risks of treatment with a PD-1/PD-L1 blocking antibody prior to or after an allogeneic HSCT.
Based on its mechanism of action, LOQTORZI can cause fetal harm when administered to a pregnant woman. Animal studies have demonstrated that inhibition of the PD-1/PD-L1 pathway can lead to increased risk of immune-mediated rejection of the developing fetus resulting in fetal death. Advise women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with LOQTORZI and for 4 months after the last dose [see Use In Specific Populations].
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Inform patients of the risk of immune-mediated adverse reactions that may be severe or fatal, may occur after discontinuation of treatment, and may require corticosteroid treatment and interruption or discontinuation of LOQTORZI. These reactions may include:
Advise patients to contact their healthcare provider immediately for signs or symptoms of infusion-related reactions [see WARNINGS AND PRECAUTIONS].
Advise patients of the risk of post-allogeneic hematopoietic stem cell transplantation complications [see WARNINGS AND PRECAUTIONS].
Advise women not to breastfeed during treatment with LOQTORZI and for 4 months after the last dose [see Use In Specific Populations].
Advise patients of the importance of keeping scheduled appointments for blood work or other laboratory tests [see WARNINGS AND PRECAUTIONS].
No studies have been performed to test the potential of toripalimab-tpzi for carcinogenicity or genotoxicity.
Fertility studies have not been conducted with toripalimab-tpzi. In 4-week and 26-week repeatdose toxicology studies in sexually mature cynomolgus monkeys, there were no adverse or notable effects in the male and female reproductive organs.
Based on its mechanism of action, LOQTORZI can cause fetal harm when administered to a pregnant woman [see CLINICAL PHARMACOLOGY]. There are no available data on the use of LOQTORZI in pregnant women. Animal studies have demonstrated that inhibition of the PD-1/PD-L1 pathway can lead to increased risk of immune-mediated rejection of the developing fetus and result in fetal death (see Data). Human IgG4 immunoglobulins (IgG4) are known to cross the placenta; therefore, LOQTORZI can potentially be transmitted from the mother to the developing fetus. Advise women of the potential risk to a fetus.
In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Animal Data
Animal reproduction studies have not been conducted with LOQTORZI to evaluate its effect on reproduction and fetal development. A central function of the PD-1/PD-L1 pathway is to preserve pregnancy by maintaining maternal immune tolerance to the fetus. In murine models of pregnancy, blockade of PD-L1 signaling has been shown to disrupt tolerance to the fetus and to result in an increase in fetal loss; therefore, potential risks of administering LOQTORZI during pregnancy could include increased rates of abortion or stillbirth. As reported in the literature, there were no malformations related to the blockade of PD-1/PD-L1 signaling in the offspring of these animals; however, immune-mediated disorders occurred in PD-1 and PD-L1 knockout mice. Based on its mechanism of action, fetal exposure to toripalimab-tpzi may increase the risk of developing immune-mediated disorders or altering the normal immune response.
There are no data on the presence of toripalimab-tpzi in human milk or its effects on the breastfed child or on milk production. Maternal IgG is known to be present in human milk. The effects of local gastrointestinal exposure and limited systemic exposure in the breastfed child to toripalimab-tpzi are unknown. Because of the potential for serious adverse reactions in breastfed children, advise lactating women not to breastfeed during treatment with LOQTORZI and for 4 months after the last dose.
LOQTORZI can cause fetal harm when administered to a pregnant woman [see Use In Specific Populations].
Verify the pregnancy status of females of reproductive potential prior to initiating LOQTORZI [see Use In Specific Populations].
Females
Advise females of reproductive potential to use effective contraception during treatment with LOQTORZI and for 4 months after the last dose.
The safety and effectiveness of LOQTORZI have not been established in pediatric patients [see INDICATIONS AND USAGE].
Of the 146 patients with NPC who were treated with LOQTORZI in combination with cisplatin and gemcitabine 7 (4.8%) were 65 years or older; there were no patients 75 years and older. Clinical studies of LOQTORZI in combination with cisplatin and gemcitabine did not include a sufficient number of patients aged 65 years and over with NPC to determine whether they respond differently from younger patients.
Of the 851 patients with tumor types including nasopharyngeal carcinoma or other types of tumors from the safety pool treated with LOQTORZI as a single agent, 171 (20%) patients were 65 years or older and 13 (1.5%) patients were 75 years and older. No overall differences in safety were observed between elderly patients and younger patients [see ADVERSE REACTIONS].
Of the 190 patients with NPC treated with LOQTORZI as single agent, 10 (5%) patients were 65 years or older; there were no patients 75 years and older. Clinical studies of LOQTORZI did not include sufficient numbers of patients aged 65 years and over with NPC to determine whether they respond differently from younger patients.
No Information Provided
None.
Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Toripalimab-tpzi is a humanized IgG4 monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathwaymediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth.
The toripalimab-tpzi exposure-response relationships and time course of pharmacodynamic response are not fully characterized.
Toripalimab-tpzi pharmacokinetic parameters are presented as geometric mean (coefficient of variation [CV]%) unless otherwise noted. Toripalimab-tpzi concentrations increased in nonlinearly over the dose range of 0.3 to 10 mg/kg every two weeks (0.1 to 3.3 times the approved recommended 3 mg/kg dosage in a 64 kg patient). Steady state was reached by Week 7. The mean accumulation ratio was approximately 1.4 for maximum concentration (Cmax) and 1.9 for area under the serum concentration curve (AUC) following multiple doses at the approved recommended dosages of 240 mg Q3W in combination with cisplatin and gemcitabine and 3 mg/kg Q2W as monotherapy.
The mean volume of distribution at steady state (Vss) of toripalimab-tpzi was 3.7 L (27%).
The mean clearance (CL) was 14.9 mL/h (31%) after the first dose and 9.5 mL/h (36%) at steady state. The mean terminal half-life (t½) (± standard deviation) was 10 ± 1.5 days after the first dose and 18 ± 9.4 days at steady state.
Metabolism
Toripalimab-tpzi is expected to be metabolized into small peptides by catabolic pathways.
No clinically significant differences in the pharmacokinetics were observed based on age (21 to 85 years), body weight (32 to 164 kg), sex, race (White and Asian), concomitant chemotherapy, mild renal impairment (creatinine clearance [CLcr] 60 to 89 mL/min), mild hepatic impairment (total bilirubin > 1 to 1.5 times ULN with any AST or total bilirubin ≤ ULN with AST > ULN), tumor burden and primary cancer.
The effect of moderate (total bilirubin >1.5 to 3 times ULN and any AST) or severe (total bilirubin > 3 times ULN and any AST) hepatic impairment or of moderate (CLcr 30 to 59 mL/min) or severe (CLcr 15 to 29 mL/min) renal impairment on the pharmacokinetics of toripalimab-tpzi has not been studied.
The observed incidence of anti-drug antibodies (ADA) is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of ADA in the studies described below with the incidence of ADA in other studies, including those of LOQTORZI or of other toripalimab products.
Of the 146 evaluable patients in JUPITER-02 with nasopharyngeal cancer who received LOQTORZI 240 mg every 3 weeks for a median duration of 15.1 months, in combination with gemcitabine and cisplatin, 3.4% tested positive for treatment-emergent ADA. Of the 190 evaluable patients in study POLARIS-02 with nasopharyngeal cancer who received LOQTORZI 3 mg/kg every 2 weeks for a median duration of 3.3 months, 3.7% of patients developed treatment-emergent ADA. Neutralizing antibodies have not been tested.
Due to the low incidence of ADA, the effect of these antibodies on the pharmacokinetics, pharmacodynamics, safety, or effectiveness of LOQTORZI is unknown.
In animal models, inhibition of PD-1/PD-L1 signaling increased the severity of some infections and enhanced inflammatory responses. Mycobacterium tuberculosis-infected PD-1 knockout mice exhibit markedly decreased survival compared with wild-type controls, which correlated with increased bacterial proliferation and inflammatory responses in these animals. PD-1 blockade using a primate anti-PD1 antibody was also shown to exacerbate M. tuberculosis infection in rhesus macaques. PD-1 and PD-L1 knockout mice and mice receiving PD-L1 blocking antibody have also shown decreased survival following infection with lymphocytic choriomeningitis virus.
The efficacy of LOQTORZI in combination with cisplatin and gemcitabine was investigated in JUPITER-02 (NCT03581786), a randomized, multicenter, single region, double-blind, placebo-controlled trial in 289 patients with metastatic or recurrent, locally advanced NPC who had not received previous systemic chemotherapy for recurrent or metastatic disease. Patients with recurrent NPC after treatment with curative intent were required to have an interval of at least 6 months between the last dose of radiotherapy or chemotherapy and recurrence. Patients with autoimmune disease, other than stable hypothyroidism or Type I diabetes, and patients who required systemic immunosuppression were ineligible.
Randomization was stratified according to Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) (0 versus 1) and disease stage (recurrent versus metastatic). Patients were randomized (1:1) to receive one of the following treatments:
Treatment with LOQTORZI or placebo continued until disease progression per RECIST v1.1, unacceptable toxicity, or a maximum of 2 years. Administration of LOQTORZI was permitted beyond radiographic progression if the patient was deriving benefit as assessed by the investigator. Tumor assessments were performed every 6 weeks for the first 12 months and every 9 weeks thereafter. The main efficacy outcome measure was Blinded Independent Review Committee (BIRC)-assessed progression-free survival (PFS) according to RECIST v1.1. Additional efficacy outcome measures include BIRC-assessed overall response rate (ORR) and overall survival (OS).
The study population characteristics were: median age of 48 years (range: 19 to 72), 4.8% age 65 or older, 83% male, 100% Asian, and 57% had ECOG PS of 0. Eighty-six percent of patients had metastatic disease at study entry. Histological subtypes of NPC included 98% non-keratinizing, 1% keratinizing squamous cell carcinoma, and 1% did not have the subtype identified.
Efficacy results of the pre-specified interim analysis of PFS and final analysis of OS are summarized in Table 7 and Figure 1 below. The trial demonstrated statistically significant improvements in BIRC-assessed PFS, ORR and OS for patients randomized to LOQTORZI in combination with cisplatin/gemcitabine compared to cisplatin and gemcitabine with placebo.
Table 7: Efficacy Results in JUPITER-02
| Endpoints | LOQTORZI Cisplatin/ Gemcitabine N =146 |
Placebo Cisplatin/ Gemcitabine N =143 |
| BIRC-Assessed Progression-free Survival1 | ||
| Number of Events, n (%) | 49 (34) | 79 (55) |
| Median, months (95% CI) | 11.7 (11.0, NE) | 8.0 (7.0, 9.5) |
| Hazard Ratio (95% CI)3 | 0.52 (0.36, 0.74) | |
| p-value4 | 0.0003 | |
| BIRC-Assessed Overall Response Rate1 | ||
| ORR, % (95% CI) | 77 (70, 84) | 66 (58, 74) |
| Complete Response Rate (%) | 19 | 11 |
| Partial Response Rate (%) | 58 | 55 |
| p-value 5 | 0.0353 | |
| BIRC-Assessed Duration of Response | ||
| Median, months | 10.0 | 5.7 |
| (95% CI) | (8.8, NE) | (5.4, 6.8) |
| Overall Survival2 | ||
| Number of Deaths, n (%) | 57 (39) | 76 (53) |
| Median, months | NR | 33.7 |
| (95% CI) | (38.7, NE) | (27.0, 44.2) |
| Hazard Ratio (95% CI)3 | 0.63 (0.45, 0.89) | |
| p-value6 | 0.0083 | |
| 1PFS and ORR results are based on the pre-specified interim analysis with data cutoff of May 30, 2020. 2OS results are based on the final analysis with a data cutoff of November 18, 2022. 3Based on the stratified Cox proportional-hazards model using the stratification factors at randomization, ECOG performance status and disease stage. 4Two-sided p-value, based on the stratified log-rank test, as compared with an alpha boundary of 0.010. 5Two-sided p-value, based upon Cochran-Mantel-Haenszel test. 6Two-sided p-value, based on the stratified log-rank test, as compared with an alpha boundary of 0.049995. BIRC=blinded independent review committee; CI= confidence interval; NR=Not Reached; NE=Not estimable. |
||
Figure 1: Kaplan-Meier Curves of Overall Survival for JUPITER-02
 |
The efficacy of LOQTORZI was investigated in POLARIS-02 (NCT 02915432), an open-label, multicenter, multicohort trial conducted in a single country. The trial included a total of 172 patients with unresectable or metastatic NPC who had received prior platinum-based chemotherapy for treatment of recurrent or metastatic NPC or had disease progression within 6 months of completion of platinum-based chemotherapy administered as neoadjuvant, adjuvant, or definitive chemoradiation treatment for locally advanced disease. Key exclusion criteria included previous treatment with an anti-PD-(L)1 antibody; active autoimmune disease or other medical conditions requiring immunosuppressive therapy. Patients received LOQTORZI 3 mg/kg intravenously every 2 weeks until disease progression per RECIST v1.1 or unacceptable toxicity. Tumor response assessments were performed every 8 weeks for the first year and every 12 weeks thereafter. The major efficacy outcome measures were confirmed ORR and duration of response (DOR) as assessed by a Blinded Independent Review Committee (BIRC) using RECIST v1.1.
The median age was 45 years (range: 22 to 68), 4.1% age 65 or older, 83% male, 100% Asian, and Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 (37%). Patients had received a median of 2 prior systemic therapies for recurrent/metastatic disease (range: 1-13). Ninety-five percent of patients had metastatic disease, 95% had non-keratinizing NPC, 2.9% had keratinizing squamous cell carcinoma and 1.7% did not have the subtype identified.
Efficacy results for POLARIS-02 are summarized in Table 8 below.
Table 8: Efficacy Results for POLARIS-02
| Endpoint | LOQTORZI (N=172) |
| BIRC-Assessed Overall Response Rate1 | |
| Overall Response Rate, % | 21 |
| (95% CI) | (15, 28) |
| Complete Response Rate, % | 2.3 |
| Partial Response Rate, % | 19 |
| BIRC-Assessed Duration of Response (DOR) | (N = 36) |
| Median, months | 14.9 |
| (95% CI) | (10.3, NE) |
| Patients with DOR ≥ 6 months2, n (%) | 30 (83%) |
| Patients with DOR ≥ 12 months2, n (%) | 14 (39%) |
| CI=confidence interval. n=number. NE = not estimable. 1 Confirmed overall response rate assessed by BIRC 2 Based on observed duration of response BIRC=blinded independent review committee |
|
No information provided. Please refer to the WARNINGS AND PRECAUTIONS section.
